APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-oncology Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-oncology Biopharmaceuticals Market Outlook and Growth Opportunities 2026

20 December 2025215 pages

Choose your research edition.

Industry ResearchNon-oncology Biopharmaceuticals Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-oncology Biopharmaceuticals Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Non-oncology Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-oncology Biopharmaceuticals Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-oncology Biopharmaceuticals Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Non-oncology Biopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-oncology Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-oncology Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-oncology Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-oncology Biopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-oncology Biopharmaceuticals market include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Merck, Mylan and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Non-oncology Biopharmaceuticals market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-oncology Biopharmaceuticals and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-oncology Biopharmaceuticals revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Non-oncology Biopharmaceuticals market.

Non-oncology Biopharmaceuticals Segment by Company

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Merck

Mylan

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Biogen

Amgen

AbbVie

AstraZeneca

UCB Pharma

Swedish Orphan Biovitrum

LEO Pharma

Elusys Therapeutics

Bristol-Myers Squibb

Boehringer Ingelheim

Alexion Pharmaceuticals

Non-oncology Biopharmaceuticals Segment by Type

Biologics

Biosimilars

Non-oncology Biopharmaceuticals Segment by Application

Immunology

Endocrinology

Others

Non-oncology Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Non-oncology Biopharmaceuticals status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Non-oncology Biopharmaceuticals key companies, revenue, market share, and recent developments.

3. To split the Non-oncology Biopharmaceuticals breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Non-oncology Biopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-oncology Biopharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze Non-oncology Biopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-oncology Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-oncology Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-oncology Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-oncology Biopharmaceuticals industry.

Chapter 3: Detailed analysis of Non-oncology Biopharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Non-oncology Biopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Non-oncology Biopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-oncology Biopharmaceuticals Industry Trends Table 2. Non-oncology Biopharmaceuticals Industry Drivers Table 3. Non-oncology Biopharmaceuticals Industry Opportunities and Challenges Table 4. Non-oncology Biopharmaceuticals Industry Restraints Table 5. Global Non-oncology Biopharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-oncology Biopharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global Non-oncology Biopharmaceuticals Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Non-oncology Biopharmaceuticals Key Company Manufacturing Base & Headquarters Table 9. Global Non-oncology Biopharmaceuticals Company, Product Type & Application Table 10. Global Non-oncology Biopharmaceuticals Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Biologics Table 15. Significant Companies of Biosimilars Table 16. Global Non-oncology Biopharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Non-oncology Biopharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Non-oncology Biopharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Non-oncology Biopharmaceuticals Sales Value Share by Type (2021-2026) Table 20. Global Non-oncology Biopharmaceuticals Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunology Table 22. Significant Companies of Endocrinology Table 23. Significant Companies of Others Table 24. Global Non-oncology Biopharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Non-oncology Biopharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Non-oncology Biopharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Non-oncology Biopharmaceuticals Sales Value Share by Application (2021-2026) Table 28. Global Non-oncology Biopharmaceuticals Sales Value Share by Application (2027-2032) Table 29. Global Non-oncology Biopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Non-oncology Biopharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Non-oncology Biopharmaceuticals Sales Value Share by Region (2021-2026) Table 32. Global Non-oncology Biopharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Non-oncology Biopharmaceuticals Sales Value Share by Region (2027-2032) Table 34. Global Non-oncology Biopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Non-oncology Biopharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Non-oncology Biopharmaceuticals Sales Value Market Share by Country (2021-2026) Table 37. Global Non-oncology Biopharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Non-oncology Biopharmaceuticals Sales Value Market Share by Country (2027-2032) Table 39. Takeda Company Information Table 40. Takeda Business Overview Table 41. Takeda Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Takeda Non-oncology Biopharmaceuticals Product Portfolio Table 43. Takeda Recent Development Table 44. Teva Company Information Table 45. Teva Business Overview Table 46. Teva Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Teva Non-oncology Biopharmaceuticals Product Portfolio Table 48. Teva Recent Development Table 49. Sanofi Company Information Table 50. Sanofi Business Overview Table 51. Sanofi Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi Non-oncology Biopharmaceuticals Product Portfolio Table 53. Sanofi Recent Development Table 54. Johnson & Johnson Company Information Table 55. Johnson & Johnson Business Overview Table 56. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Johnson & Johnson Non-oncology Biopharmaceuticals Product Portfolio Table 58. Johnson & Johnson Recent Development Table 59. Novartis Company Information Table 60. Novartis Business Overview Table 61. Novartis Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Novartis Non-oncology Biopharmaceuticals Product Portfolio Table 63. Novartis Recent Development Table 64. Novo Nordisk Company Information Table 65. Novo Nordisk Business Overview Table 66. Novo Nordisk Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novo Nordisk Non-oncology Biopharmaceuticals Product Portfolio Table 68. Novo Nordisk Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck Non-oncology Biopharmaceuticals Product Portfolio Table 73. Merck Recent Development Table 74. Mylan Company Information Table 75. Mylan Business Overview Table 76. Mylan Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Mylan Non-oncology Biopharmaceuticals Product Portfolio Table 78. Mylan Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Roche Non-oncology Biopharmaceuticals Product Portfolio Table 83. Roche Recent Development Table 84. Eli Lilly Company Information Table 85. Eli Lilly Business Overview Table 86. Eli Lilly Non-oncology Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Eli Lilly Non-oncology Biopharmaceuticals Product Portfolio Table 88. Eli Lilly Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Pfizer Non-oncology Biopharmaceuticals Product Portfolio Table 93. Pfizer Recent Development Table 94. GlaxoSmithKline Company Information Table 95. GlaxoSmithKline Business Overview Table 96. GlaxoSmithKline Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Portfolio Table 98. GlaxoSmithKline Recent Development Table 99. Biogen Company Information Table 100. Biogen Business Overview Table 101. Biogen Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Biogen Non-oncology Biopharmaceuticals Product Portfolio Table 103. Biogen Recent Development Table 104. Amgen Company Information Table 105. Amgen Business Overview Table 106. Amgen Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Amgen Non-oncology Biopharmaceuticals Product Portfolio Table 108. Amgen Recent Development Table 109. AbbVie Company Information Table 110. AbbVie Business Overview Table 111. AbbVie Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. AbbVie Non-oncology Biopharmaceuticals Product Portfolio Table 113. AbbVie Recent Development Table 114. AstraZeneca Company Information Table 115. AstraZeneca Business Overview Table 116. AstraZeneca Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. AstraZeneca Non-oncology Biopharmaceuticals Product Portfolio Table 118. AstraZeneca Recent Development Table 119. UCB Pharma Company Information Table 120. UCB Pharma Business Overview Table 121. UCB Pharma Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. UCB Pharma Non-oncology Biopharmaceuticals Product Portfolio Table 123. UCB Pharma Recent Development Table 124. Swedish Orphan Biovitrum Company Information Table 125. Swedish Orphan Biovitrum Business Overview Table 126. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Portfolio Table 128. Swedish Orphan Biovitrum Recent Development Table 129. LEO Pharma Company Information Table 130. LEO Pharma Business Overview Table 131. LEO Pharma Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. LEO Pharma Non-oncology Biopharmaceuticals Product Portfolio Table 133. LEO Pharma Recent Development Table 134. Elusys Therapeutics Company Information Table 135. Elusys Therapeutics Business Overview Table 136. Elusys Therapeutics Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Portfolio Table 138. Elusys Therapeutics Recent Development Table 139. Bristol-Myers Squibb Company Information Table 140. Bristol-Myers Squibb Business Overview Table 141. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Portfolio Table 143. Bristol-Myers Squibb Recent Development Table 144. Boehringer Ingelheim Company Information Table 145. Boehringer Ingelheim Business Overview Table 146. Boehringer Ingelheim Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Portfolio Table 148. Boehringer Ingelheim Recent Development Table 149. Alexion Pharmaceuticals Company Information Table 150. Alexion Pharmaceuticals Business Overview Table 151. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Portfolio Table 153. Alexion Pharmaceuticals Recent Development Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Non-oncology Biopharmaceuticals Product Image Figure 2. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-oncology Biopharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-oncology Biopharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Biologics Image Figure 8. Biosimilars Image Figure 9. Global Non-oncology Biopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Non-oncology Biopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Non-oncology Biopharmaceuticals Sales Value Share by Type (2021-2032) Figure 12. Immunology Image Figure 13. Endocrinology Image Figure 14. Others Image Figure 15. Global Non-oncology Biopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Non-oncology Biopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Non-oncology Biopharmaceuticals Sales Value Share by Application (2021-2032) Figure 18. Global Non-oncology Biopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Non-oncology Biopharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Non-oncology Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 21. North America Non-oncology Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Non-oncology Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Non-oncology Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Non-oncology Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Non-oncology Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Non-oncology Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 27. South America Non-oncology Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Non-oncology Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Non-oncology Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Immunology
  • Endocrinology
  • Others
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Amgen
  • AbbVie
  • AstraZeneca
  • UCB Pharma
  • Swedish Orphan Biovitrum
  • LEO Pharma
  • Elusys Therapeutics
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Alexion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Non-oncology Biopharmaceuticals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Non-oncology Biopharmaceuticals Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Non-oncology Biopharmaceuticals Market Dynamics
  1. 2.1 Non-oncology Biopharmaceuticals Industry Trends
  2. 2.2 Non-oncology Biopharmaceuticals Industry Drivers
  3. 2.3 Non-oncology Biopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 Non-oncology Biopharmaceuticals Industry Restraints
3 Non-oncology Biopharmaceuticals Market by Company
  1. 3.1 Global Non-oncology Biopharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global Non-oncology Biopharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global Non-oncology Biopharmaceuticals Company Ranking (2024-2026)
  4. 3.4 Global Non-oncology Biopharmaceuticals Company Manufacturing Base and Headquarters
  5. 3.5 Global Non-oncology Biopharmaceuticals Company Product Type and Application
  6. 3.6 Global Non-oncology Biopharmaceuticals Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Non-oncology Biopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Non-oncology Biopharmaceuticals Market by Type
  1. 4.1 Non-oncology Biopharmaceuticals Type Introduction
  2. 4.1.1 Biologics
  3. 4.1.2 Biosimilars
  4. 4.2 Global Non-oncology Biopharmaceuticals Sales Value by Type
  5. 4.2.1 Global Non-oncology Biopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Non-oncology Biopharmaceuticals Sales Value by Type (2021-2032)
  7. 4.2.3 Global Non-oncology Biopharmaceuticals Sales Value Share by Type (2021-2032)
5 Non-oncology Biopharmaceuticals Market by Application
  1. 5.1 Non-oncology Biopharmaceuticals Application Introduction
  2. 5.1.1 Immunology
  3. 5.1.2 Endocrinology
  4. 5.1.3 Others
  5. 5.2 Global Non-oncology Biopharmaceuticals Sales Value by Application
  6. 5.2.1 Global Non-oncology Biopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-oncology Biopharmaceuticals Sales Value by Application (2021-2032)
  8. 5.2.3 Global Non-oncology Biopharmaceuticals Sales Value Share by Application (2021-2032)
6 Non-oncology Biopharmaceuticals Regional Value Analysis
  1. 6.1 Global Non-oncology Biopharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-oncology Biopharmaceuticals Sales Value by Region (2021-2032)
  3. 6.2.1 Global Non-oncology Biopharmaceuticals Sales Value by Region: 2021-2026
  4. 6.2.2 Global Non-oncology Biopharmaceuticals Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Non-oncology Biopharmaceuticals Sales Value (2021-2032)
  7. 6.3.2 North America Non-oncology Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Non-oncology Biopharmaceuticals Sales Value (2021-2032)
  10. 6.4.2 Europe Non-oncology Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Non-oncology Biopharmaceuticals Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Non-oncology Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Non-oncology Biopharmaceuticals Sales Value (2021-2032)
  16. 6.6.2 South America Non-oncology Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Non-oncology Biopharmaceuticals Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Non-oncology Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 Non-oncology Biopharmaceuticals Country-level Value Analysis
  1. 7.1 Global Non-oncology Biopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-oncology Biopharmaceuticals Sales Value by Country (2021-2032)
  3. 7.2.1 Global Non-oncology Biopharmaceuticals Sales Value by Country (2021-2026)
  4. 7.2.2 Global Non-oncology Biopharmaceuticals Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Non-oncology Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Non-oncology Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Non-oncology Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Non-oncology Biopharmaceuticals Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Non-oncology Biopharmaceuticals Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Non-oncology Biopharmaceuticals Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Non-oncology Biopharmaceuticals Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Non-oncology Biopharmaceuticals Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Non-oncology Biopharmaceuticals Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Non-oncology Biopharmaceuticals Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mylan Non-oncology Biopharmaceuticals Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Non-oncology Biopharmaceuticals Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Non-oncology Biopharmaceuticals Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Non-oncology Biopharmaceuticals Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 GlaxoSmithKline
  68. 8.12.1 GlaxoSmithKline Company Information
  69. 8.12.2 GlaxoSmithKline Business Overview
  70. 8.12.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  71. 8.12.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Product Portfolio
  72. 8.12.5 GlaxoSmithKline Recent Developments
  73. 8.13 Biogen
  74. 8.13.1 Biogen Company Information
  75. 8.13.2 Biogen Business Overview
  76. 8.13.3 Biogen Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biogen Non-oncology Biopharmaceuticals Product Portfolio
  78. 8.13.5 Biogen Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Non-oncology Biopharmaceuticals Product Portfolio
  84. 8.14.5 Amgen Recent Developments
  85. 8.15 AbbVie
  86. 8.15.1 AbbVie Company Information
  87. 8.15.2 AbbVie Business Overview
  88. 8.15.3 AbbVie Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AbbVie Non-oncology Biopharmaceuticals Product Portfolio
  90. 8.15.5 AbbVie Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Non-oncology Biopharmaceuticals Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 UCB Pharma
  98. 8.17.1 UCB Pharma Company Information
  99. 8.17.2 UCB Pharma Business Overview
  100. 8.17.3 UCB Pharma Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  101. 8.17.4 UCB Pharma Non-oncology Biopharmaceuticals Product Portfolio
  102. 8.17.5 UCB Pharma Recent Developments
  103. 8.18 Swedish Orphan Biovitrum
  104. 8.18.1 Swedish Orphan Biovitrum Company Information
  105. 8.18.2 Swedish Orphan Biovitrum Business Overview
  106. 8.18.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Portfolio
  108. 8.18.5 Swedish Orphan Biovitrum Recent Developments
  109. 8.19 LEO Pharma
  110. 8.19.1 LEO Pharma Company Information
  111. 8.19.2 LEO Pharma Business Overview
  112. 8.19.3 LEO Pharma Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  113. 8.19.4 LEO Pharma Non-oncology Biopharmaceuticals Product Portfolio
  114. 8.19.5 LEO Pharma Recent Developments
  115. 8.20 Elusys Therapeutics
  116. 8.20.1 Elusys Therapeutics Company Information
  117. 8.20.2 Elusys Therapeutics Business Overview
  118. 8.20.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Product Portfolio
  120. 8.20.5 Elusys Therapeutics Recent Developments
  121. 8.21 Bristol-Myers Squibb
  122. 8.21.1 Bristol-Myers Squibb Company Information
  123. 8.21.2 Bristol-Myers Squibb Business Overview
  124. 8.21.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Portfolio
  126. 8.21.5 Bristol-Myers Squibb Recent Developments
  127. 8.22 Boehringer Ingelheim
  128. 8.22.1 Boehringer Ingelheim Company Information
  129. 8.22.2 Boehringer Ingelheim Business Overview
  130. 8.22.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Portfolio
  132. 8.22.5 Boehringer Ingelheim Recent Developments
  133. 8.23 Alexion Pharmaceuticals
  134. 8.23.1 Alexion Pharmaceuticals Company Information
  135. 8.23.2 Alexion Pharmaceuticals Business Overview
  136. 8.23.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Portfolio
  138. 8.23.5 Alexion Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst